Case series: MRD negativity assessment using $^{11}$C-Acetate PET with 3-weekly daratumumab-based quadruplet induction in newly diagnosed multiple myeloma

Cheong Ngai, Shaji Kumar, Garrett Chi-lai Ho, Sirong Chen and Chor-sang Chim

Abstract: Complete response (CR) is an important favorable factor for survival in multiple myeloma (MM). However, CR patients continue to relapse, especially in the presence of minimal residual disease (MRD). Bone marrow (BM) MRD is predictive of progression-free survival (PFS) in MM. However, myeloma outside the BM aspiration site may result in subsequent relapse despite MRD-negativity. Therefore, positron emission tomography-computed tomography (PET-CT) based on F-fluorodeoxyglucose (FDG) is a complementary tool to monitor residual disease in MM. However, FDG may miss myeloma lesions that are not FDG-avid. On the other hand, $^{11}$C-Acetate (ACT) has been found to be a more sensitive and specific tracer than FDG in MM. Recently, the addition of daratumumab to bortezomib, thalidomide, dexamethasone (VTd) or bortezomib, lenalidomide, dexamethasone (VRd) backbone has been proven to improve outcomes. Herein, we report three newly-diagnosed MM patients achieving deep responses with imaging CR using ACT PET in addition to conventional immunofixation CR and MRD-negative CR after a 3-weekly daratumumab-based quadruplet induction regimen.

Keywords: 3-weekly daratumumab, $^{11}$C-Acetate PET, MRD negativity, newly diagnosed multiple myeloma, quadruplet induction

Received: 25 January 2021; revised manuscript accepted: 11 June 2021.

Introduction

Multiple myeloma (MM) is a clonal hematopoietic neoplasm of the plasma cells in the bone marrow. With remarkable advances in the advent of novel agents, there is an increase in the rate of complete response (CR), which, according to the International Myeloma Working Group, is defined as negative immunofixation in the serum and urine and disappearance of any soft tissue plasmacytomas, and <5% plasma cells in the bone marrow. Nevertheless, MM continues to relapse, especially in the presence of minimal residual disease (MRD). Therefore, MRD-negative CR, which signified a deeper response, was defined.

Current methods to detect MRD include next-generation flow cytometry (NGF) and next-generation sequencing (NGS) that possess a sensitivity of up to $10^{-6}$. Apart from the proprietary NGS method by ClonoSeq, the usage of the LymphoTrack system, with a sensitivity of $10^{-5}$ has been recently validated. On the other hand, previous studies have demonstrated the prognostic effect of $^{18}$F-fluorodeoxyglucose (FDG) positron emission tomography-computed tomography (PET-CT). However, given the limitation of FDG-PET in MM, other tracers have been investigated, including, but not limited to, $^{18}$F-choline and $^{11}$C-choline, $^{11}$C-acetate (ACT), $^{11}$C-methionine, $^{68}$Ga-pentixafor, and...
$^{89}\text{Zr}}$-Daratumumab. As myeloma plasma cells have been shown to utilize lipid metabolism, ACT is a potentially useful tracer in MM. Indeed, in our previous pilot study using dual-tracer PET-CT with both ACT and FDG, ACT was shown to be a much more sensitive and specific tracer than FDG for MM.

The addition of daratumumab (Dara) to a bortezomib, thalidomide, dexamethasone (VTd) or a bortezomib, lenalidomide, dexamethasone (VRd) triplet induction regimen has been shown to result in a higher CR rate and MRD-negativity in newly diagnosed MM, translating into superior progression-free survival (PFS). However, daratumumab is expensive; therefore, it is unaffordable for many patients, especially in resource-constrained regions, including Hong Kong. In view of the long plasma half-life of daratumumab, as well as the success of 3-weekly rituximab in the rituximab, cyclophosphamide, hydroxydaunomycin, vincristine (R-CHOP) regimen for lymphoma, a 3-weekly daratumumab-based induction regimen has been proposed and adopted in our center.

Herein, we report three newly diagnosed MM patients achieving imaging CR with ACT PET, in addition to conventional immunofixation CR and MRD-negative CR after a 3-weekly daratumumab-based induction regimen.

Case presentation

We present three cases of newly diagnosed MM. Two were transplant candidates, whereas one was transplant ineligible. The characteristics and investigation results of the three patients at diagnosis were summarized in Table 1. Patients were staged using the International staging system (ISS), a prognostic scoring system comprising beta-2-microglobulin and albumin, enabling stratification of MM patients into stage I, II, or III with inferior survival in patients with higher ISS stage. All received a four-drug Dara-based regimen with the addition of Dara to a triplet regimen comprising a bortezomib (V), an immunomodulatory agent (IMiD) with either thalidomide (T) or lenalidomide (R), and dexamethasone (d), followed by autologous stem cell transplant (ASCT) if the patient is transplant eligible, and then maintenance with single agent IMiD. The choice of IMiD depended on the affordability of the patient, as thalidomide is provided by the Hospital Authority, but lenalidomide is a self-financed item.

The Dara-based regimen used was a 3-weekly regimen. Daratumumab was given as an infusion at a dose of 16 mg/kg once every three weeks. Bortezomib was given at a dose of 1.3 mg/m$^2$ once a week. Lenalidomide was given at a dose of 25 mg daily five times per week, and thalidomide was given at a dose of 100–200 mg daily. Dexamethasone was kept at 20 mg daily two times per week. After achieving $\geq$VGPR, patients received single agent IMiD maintenance, thalidomide 50 mg daily, or lenalidomide 15 mg daily, till disease progression.

MRD assessment in our patients was performed in the bone marrow samples, either 30 days and 90 days after ASCT for transplant candidates, or within 3 months after CR for non-transplant candidates, by NGS using the LymphoTrack system with a sensitivity of $10^{-5}$. Our patients had dual-tracer PET-CT at diagnosis and after the achievement of MRD-negative CR using both ACT and FDG as tracer as previously described. The exact time of reassessment PET-CT was generally within 6 months after MRD-negative CR but would be adjusted according to the next follow-up date or patient preference.

Patient 1

A 63-year-old man was diagnosed with International Staging System stage 3 (ISS3), cytogenetic high-risk immunoglobulin G (IgG) MM. He presented with weight loss of eight kilograms over six months and was found to have anemia with hemoglobin (Hb) 10 g/dl and reverse albumin/globulin ratio. Serum creatinine, calcium, and LDH levels were normal. Serum protein electrophoresis (SPE) showed monoclonal IgG lambda of 26.54 g/l. Bone marrow yielded 20% plasma cells with lambda light chain restriction. Fluorescence in situ hybridization (FISH) showed both t(4;14) and del(17p). Serum albumin measured 33 g/l and beta-2-microglobulin (B2M) 8.21 µg/ml; hence, the ISS3 IgGL MM with two high-risk cytogenetic alterations. Dual ACT/FDG PET-CT showed diffusely accentuated marrow activities on ACT-PET with maximum standard unit value (SUVmax) 5.4 (normal ACT SUVmax $<3.8$) while marrow FDG activity was only marginally increased (FDG SUVmax 3.3, normal SUVmax $<3.1$). No focal hypermetabolic lesion was seen with either tracer. This patient achieved immunofixation-negative CR after eight cycles of Dara-VRd prior to autologous stem cell transplant (ASCT) in March 2020,
followed by lenalidomide maintenance thereafter. BM on Day 30 and Day 90 after ASCT confirmed MRD-negative CR (Figure 1) and dual-tracer PET-CT five months after MRD-negative CR showed metabolic CR with complete resolution of the previous diffusely increased ACT uptake in bone marrow (ACT SUVmax 2.9, FDG SUVmax 1.9). Currently, he remained in CR 17 months since diagnosis.

**Patient 2**

A 60-year-old woman was diagnosed with ISS2, cytogenetic standard-risk immunoglobulin A (IgA) MM. She presented with symptomatic anemia with Hb 7.3 g/dl. Serum creatinine, calcium, and LDH levels were normal. SPE showed monoclonal IgA Kappa of 33.53 g/l. BM showed 96% plasma cells with kappa light chain restriction. FISH was negative for high-risk cytogenetics including del(17p), t(4;14) and t(14;16). Serum albumin was 37 g/l and B2M was 4.04 μg/ml; hence, ISS stage 2 IgAK MM. Dual-tracer PET-CT showed diffuse BM uptake by ACT (SUVmax 4.1) with multiple ACT-avid focal bone lesions. She achieved CR after five cycles of
Dara-VTd induction, followed by ASCT, and then thalidomide maintenance. Both Day 30 and Day 90 post-ASCT BM yielded MRD negativity, hence MRD-negative CR. Reassessment dual-tracer PET-CT one month after MRD-negative CR showed complete ACT-PET metabolic response. (Figure 2) She is currently in CR 12 months since diagnosis.

**Patient 3**
A 73-year-old man was diagnosed with ISS1, cytogenetic high-risk IgA MM. He presented with a protracted viral illness in June 2018. Blood tests showed Hb 10.3 g/dl, with normal creatinine and calcium level. SPE showed monoclonal IgA Kappa with a level of 28.31 g/l. BM yielded 58% plasma cells. FISH showed both t(4;14) and gain(1q21). Serum LDH was normal, and albumin was 43 g/l with B2M level of 2.55 μg/ml; hence, ISS stage I IgAK MM. Dual-tracer PET-CT showed ACT-avid (SUVmax 4.1) diffusely increased bone marrow activity in the axial skeleton without focal lesions. FDG-PET marrow activity was normal (SUVmax 2.1). He achieved MRD-negative CR with seven cycles of Dara-VRd induction. Subsequent dual-tracer PET-CT two months after MRD-negative CR showed an interval partial response with normalization of previous diffuse ACT-avid BM activity (SUVmax 1.7) in the axial skeleton except a solitary lesion on the left side of T3 vertebra showing decreased ACT clearance (SUVmax 2.6) compared with the rest of normalized BM activity. As he was not a transplant candidate, he was put on single agent lenalidomide maintenance. Reassessment dual-tracer PET-CT nine months after last PET-CT showed complete metabolic CR, including the T3 lesion. A repeated MRD study 27 months after diagnosis showed persistent MRD-negative CR in August 2020. Currently, he is in CR 30 months after diagnosis.

**Discussion**
Daratumumab is an anti-CD38 monoclonal antibody leading to myeloma cell killing via direct induction of apoptosis, Fc-related mechanism of myeloma cytotoxicity, and eradication of CD38+ve immunosuppressive cells in the BM microenvironment. The addition of daratumumab to VTd and VRd has been shown to confer superior CR rate as demonstrated in two large randomized controlled trials. In the Cassiopeia study, the rate of ≥CR post-ASCT was higher with the addition of Dara to VTd (Dara-VTd: 39% versus VTd: 26%), resulting in a superior PFS (18-month PFS of Dara-VTd: 93% versus VTd: 85%). Similarly, in the Griffin study, the rate of ≥CR post-consolidation was superior in Dara-VRd than VRd arm (51.5% versus 42.3%), together with better PFS (24-month PFS of Dara-VRd: 95.8% versus VRd: 89.8%). On the other hand, in non-transplant candidates, Dara-Rd has been shown to confer a superior rate of ≥CR and PFS than Rd in the MAIA study. In these clinical trials, the daratumumab used was mainly on a weekly basis during induction. However, despite the less frequent use of daratumumab, our patients achieved not only immunofixation-negative CR but also NGS MRD-negative and ACT PET-negative CR, including two patients (patients 1 and 3) harboring ultra-high-risk cytogenetics.
[t(4;14) plus TP53 del or gain (1q21)]\(^{18}\) which was associated with inferior outcomes than those with the single high-risk cytogenetic alteration.\(^{19}\)

Depth of response in MM is highly prognostic of survival. Patients achieving immunofixation-neg-ative CR had superior survival than those achieving very good partial response (VGPR) with negative SPE but positive immunofixation.\(^{20}\) Moreover, MRD-negativity has been shown to confer superior PFS in MM. In a recent IFM-DFCI (Intergroupe Francophone du Myelome/Dana-Farber Cancer Institute) study that interrogated if ASCT was necessary in the era of VRD triplet induction, MRD-negativity was shown to confer superior PFS using NGS with ClonoSeq.\(^{21}\) ClonoSeq is a proprietary NGS platform, for which a sensitivity of \(10^{-6}\) has been demonstrated in myeloma patients.\(^{22,23}\) On the other hand, we have validated a standardized protocol using the LymphoTrack platform and verified experimentally that a sensitivity of \(10^{-5}\) was consistently achieved in each and every MRD BM sample by including a spike-in sensitivity control at a concentration of \(10^{-5}\) in each MRD BM sample.\(^{3,4}\)

As BM infiltration by MM plasma cells is often focal and patchy, MRD-negativity at a single BM site cannot rule out myeloma infiltration outside the BM aspiration site. Therefore, PET-CT, empowered to detect hypermetabolic intramedul-lary or extramedullary bone lesions, is complementary to BM MRD to document remission status in MM. Indeed, the number of hypermetabolic bone lesions was shown to be prognostic of survival,\(^{6}\) and complete resolution of hypermetabolic BM lesions prognostic in MM in CR.\(^{5}\) FDG PET has been widely used for this purpose. However, we have reported that FDG is not a PET tracer sensitive or specific enough for MM. In our dual-tracer (using both ACT and FDG) PET-CT study in MM,\(^{9}\) a significant proportion of patients in whom no diffuse or focal FDG-avid BM lesions were found, hypermetabolic ACT-avid lesions were detected. This is also illustrated in patients 2 and 3, in whom diffusely accentuated
marrow activities were only detected by ACT-PET. Of note, in diagnostic dual-tracer PET-CT of patient 2, multiple focal bone lesions were only found to be ACT-avid without FDG-avidity. Moreover, even in patients who had both FDG and ACT-avid bone marrow lesions, higher SUVmax was noted by ACT than FDG, which can be illustrated by patient 1 with diagnostic dual-tracer PET-CT showing diffuse BM uptake by both tracers yet higher ACT uptake than FDG (SUVmax of ACT: 5.4 versus FDG: 3.3). An in vitro study\(^8\) on the biochemical derangement of mouse MM cells showed that ACT utilization was elevated because an enzyme fatty acid synthase (FASN) activity was upregulated for energy production and lipid synthesis, unlike many tumors that commonly prefer Warburg’s glycolysis for tumor growth. Therefore, the underlying molecular basis explains why ACT is a much more sensitive and specific tracer for MM than FDG. Patient 3 had residual hypermetabolic ACT-avid T3 lesion upon MRD-negative CR after induction that turned eumetabolic in a subsequent PET-CT. Without a biopsy, the nature of the residual T3 lesion could not be ascertained. However, as the ACT-avid T3 lesion resolved completely in the follow-up PET-CT later, the lesion was likely due to residual disease.

In conclusion, 3-weekly daratumumab-based quadruplet induction regimen appeared effective in achieving deep responses with ACT PET-CR in addition to the widely-used conventional immunofixation CR and MRD-negative CR in newly diagnosed multiple myeloma. However, future validation with additional studies of the long-term efficacy, cost, and quality-of-life assessment would be required.

Acknowledgements
Not applicable.

Author contributions
CN drafted the manuscript. CSC treated the patients and drafted the manuscript. GCH and SC provided PET-CT images. SK reviewed the manuscript and provided critical advice. All authors read and approved the final manuscript.

Conflict of interest statement
The authors declare that there is no conflict of interest.

Funding
The authors received no financial support for the research, authorship, and/or publication of this article.

Ethics approval and consent to participate
This study was approved by the Institutional Review Board of the University of Hong Kong/Hospital Authority Hong Kong West Cluster (Reference number: UW 19-108). Written informed consents were obtained from the patients.

ORCID iDs
Cheong Ngai https://orcid.org/0000-0002-6438-2170
Shaji Kumar https://orcid.org/0000-0001-5392-9284

References
1. Bai Y, Orfao A and Chim CS. Molecular detection of minimal residual disease in multiple myeloma. Br J Haematol 2018; 181: 11–26.
2. Kumar S, Paiva B, Anderson KC, et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol 2016; 17: e328–e346.
3. Yao Q, Bai Y, Orfao A, et al. Standardized minimal residual disease detection by next-generation sequencing in multiple myeloma. Front Oncol 2019; 9: 449.
4. Yao Q, Bai Y, Orfao A, et al. Upgraded standardized minimal residual disease detection by next-generation sequencing in multiple myeloma. J Mol Diagn 2020; 22: 679–684.
5. Zamagni E, Nanni C, Mancuso K, et al. PET/CT improves the definition of complete response and allows to detect otherwise unidentifiable skeletal progression in multiple myeloma. Clin Cancer Res 2015; 21: 4384–4390.
6. Bartel TB, Haessler J, Brown TL, et al. F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma. Blood 2009; 114: 2068–2076.
7. Sachpekidis C, Goldschmidt H and Dimitrakopoulou-Strauss A. Positron Emission Tomography (PET) radiopharmaceuticals in multiple myeloma. Molecules 2019; 25: 134.
8. Fontana F, Ge X, Su X, *et al.* Evaluating acetate metabolism for imaging and targeting in multiple myeloma. *Clin Cancer Res* 2017; 23: 416–429.

9. Ho C-l, Chen S, Leung YL, *et al.* 11C-acetate PET/CT for metabolic characterization of multiple myeloma: a comparative study with 18F-FDG PET/CT. *J Nucl Med* 2014; 55: 749–752.

10. Moreau P, Attal M, Hulin C, *et al.* Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study. *Lancet* 2019; 394: 29–38.

11. Voorhees PM, Kaufman JL, Laubach JP, *et al.* Daratumumab, lenalidomide, bortezomib, & dexamethasone for transplant-eligible newly diagnosed multiple myeloma: GRIFFIN. *Blood* 2020; 136: 936–945.

12. Clemens PL, Yan X, Lokhorst HM, *et al.* Pharmacokinetics of daratumumab following intravenous infusion in relapsed or refractory multiple myeloma after prior proteasome inhibitor and immunomodulatory drug treatment. *Clin Pharmacokine* 2017; 56: 915–924.

13. Maloney DG. Anti-CD20 antibody therapy for B-cell lymphomas. *N Engl J Med* 2012; 366: 2008–2016.

14. Chim CS, Wong VKC, Au YLE, *et al.* PS1432 3-weekly daratumumab-IMiD-dexamethasone is highly efficacious and cost-effective in relapsed/refractory multiple myeloma. *J Clin Oncol* 2019; 37: e19521–e19521.

15. Chim J, Wong V, AU E, *et al.* 3-weekly daratumumab-IMiD-dexamethasone is highly efficacious and cost-effective in relapsed/refractory multiple myeloma. *J Clin Oncol* 2019; 37: e19521–e19521.

16. Chim CS, Kumar SK, Orlowski RZ, *et al.* Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond. *Leukemia* 2018; 32: 252–262.

17. Facon T, Kumar S, Plesner T, *et al.* Daratumumab plus lenalidomide and dexamethasone for untreated myeloma. *N Engl J Med* 2019; 380: 2104–2115.

18. Usmani SZ, Rodriguez-Otero P, Bhutani M, *et al.* Defining and treating high-risk multiple myeloma. *Leukemia* 2015; 29: 2119–2125.

19. Baysal M, Demirci U, Umit E, *et al.* Concepts of double hit and triple hit disease in multiple myeloma, entity and prognostic significance. *Sci Rep* 2020; 10: 5991.

20. Martinez-Lopez J, Blade J, Mateos M-V, *et al.* Long-term prognostic significance of response in multiple myeloma after stem cell transplantation. *Blood* 2011; 118: 529–534.

21. Perrot A, Lauwers-Cances V, Corre J, *et al.* Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma. *Blood* 2018; 132: 2456–2464.

22. Martinez-Lopez J, Lahuerta JJ, Pepin F, *et al.* Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma. *Blood* 2014; 123: 3073–3079.

23. Mateos M-V, Dimopoulos MA, Cavo M, *et al.* Daratumumab plus bortezomib, melphalan, and prednisone for untreated myeloma. *N Engl J Med* 2018; 378: 518–528.